These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 19156529)

  • 1. Interactions between cycloguanil derivatives and wild type and resistance-associated mutant Plasmodium falciparum dihydrofolate reductases.
    Maitarad P; Kamchonwongpaisan S; Vanichtanankul J; Vilaivan T; Yuthavong Y; Hannongbua S
    J Comput Aided Mol Des; 2009 Apr; 23(4):241-52. PubMed ID: 19156529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Particular interaction between pyrimethamine derivatives and quadruple mutant type dihydrofolate reductase of Plasmodium falciparum: CoMFA and quantum chemical calculations studies.
    Maitarad P; Saparpakorn P; Hannongbua S; Kamchonwongpaisan S; Tarnchompoo B; Yuthavong Y
    J Enzyme Inhib Med Chem; 2009 Apr; 24(2):471-9. PubMed ID: 18608776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flexible diaminodihydrotriazine inhibitors of Plasmodium falciparum dihydrofolate reductase: Binding strengths, modes of binding and their antimalarial activities.
    Kamchonwongpaisan S; Charoensetakul N; Srisuwannaket C; Taweechai S; Rattanajak R; Vanichtanankul J; Vitsupakorn D; Arwon U; Thongpanchang C; Tarnchompoo B; Vilaivan T; Yuthavong Y
    Eur J Med Chem; 2020 Jun; 195():112263. PubMed ID: 32294614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3D-QSAR analysis of cycloguanil derivatives as inhibitors of A16V + S108T mutant Plasmodium falciparum dihydrofolate reductase enzyme.
    Adane L; Bharatam PV
    J Mol Graph Model; 2009 Nov; 28(4):357-67. PubMed ID: 19796975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of pyrimethamine, cycloguanil, WR99210 and their analogues with Plasmodium falciparum dihydrofolate reductase: structural basis of antifolate resistance.
    Rastelli G; Sirawaraporn W; Sompornpisut P; Vilaivan T; Kamchonwongpaisan S; Quarrell R; Lowe G; Thebtaranonth Y; Yuthavong Y
    Bioorg Med Chem; 2000 May; 8(5):1117-28. PubMed ID: 10882022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined spatial limitation around residues 16 and 108 of Plasmodium falciparum dihydrofolate reductase explains resistance to cycloguanil.
    Vanichtanankul J; Taweechai S; Uttamapinant C; Chitnumsub P; Vilaivan T; Yuthavong Y; Kamchonwongpaisan S
    Antimicrob Agents Chemother; 2012 Jul; 56(7):3928-35. PubMed ID: 22526319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A common feature-based 3D-pharmacophore model generation and virtual screening: identification of potential PfDHFR inhibitors.
    Adane L; Bharatam PV; Sharma V
    J Enzyme Inhib Med Chem; 2010 Oct; 25(5):635-45. PubMed ID: 19995305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring QSAR, pharmacophore mapping and docking studies and virtual library generation for cycloguanil derivatives as PfDHFR-TS inhibitors.
    Ojha PK; Roy K
    Med Chem; 2011 May; 7(3):173-99. PubMed ID: 21486210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of molecular docking and PSO-SVR intelligent approaches in antimalarial activity prediction of enantiomeric cycloguanil analogues.
    Inthajak K; Toochinda P; Lawtrakul L
    SAR QSAR Environ Res; 2018 Dec; 29(12):957-974. PubMed ID: 30381963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a lead inhibitor for the A16V+S108T mutant of dihydrofolate reductase from the cycloguanil-resistant strain (T9/94) of Plasmodium falciparum.
    Yuthavong Y; Vilaivan T; Chareonsethakul N; Kamchonwongpaisan S; Sirawaraporn W; Quarrell R; Lowe G
    J Med Chem; 2000 Jul; 43(14):2738-44. PubMed ID: 10893311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationship and comparative docking studies for cycloguanil analogs as PfDHFR-TS inhibitors.
    Sivaprakasam P; Tosso PN; Doerksen RJ
    J Chem Inf Model; 2009 Jul; 49(7):1787-96. PubMed ID: 19588935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conflicting requirements of Plasmodium falciparum dihydrofolate reductase mutations conferring resistance to pyrimethamine-WR99210 combination.
    Japrung D; Leartsakulpanich U; Chusacultanachai S; Yuthavong Y
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4356-60. PubMed ID: 17875995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular epidemiology of malaria in Yaounde, Cameroon. VI. Sequence variations in the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene and in vitro resistance to pyrimethamine and cycloguanil.
    Basco LK; Ringwald P
    Am J Trop Med Hyg; 2000 Feb; 62(2):271-6. PubMed ID: 10813484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homology modeling of wild type and pyrimethamine/cycloguanil-cross resistant mutant type Plasmodium falciparum dihydrofolate reductase. A model for antimalarial chemotherapy resistance.
    Santos-Filho OA; de Alencastro RB; Figueroa-Villar JD
    Biophys Chem; 2001 Jul; 91(3):305-17. PubMed ID: 11551441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In silico screening against wild-type and mutant Plasmodium falciparum dihydrofolate reductase.
    Fogel GB; Cheung M; Pittman E; Hecht D
    J Mol Graph Model; 2008 Apr; 26(7):1145-52. PubMed ID: 18037315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular modeling of wild-type and antifolate resistant mutant Plasmodium falciparum DHFR.
    Delfino RT; Santos-Filho OA; Figueroa-Villar JD
    Biophys Chem; 2002 Aug; 98(3):287-300. PubMed ID: 12128181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular dynamics of interactions between rigid and flexible antifolates and dihydrofolate reductase from pyrimethamine-sensitive and pyrimethamine-resistant Plasmodium falciparum.
    Mokmak W; Chunsrivirot S; Hannongbua S; Yuthavong Y; Tongsima S; Kamchonwongpaisan S
    Chem Biol Drug Des; 2014 Oct; 84(4):450-61. PubMed ID: 24716467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Origins of the specificity of inhibitor P218 toward wild-type and mutant PfDHFR: a molecular dynamics analysis.
    Abbat S; Jain V; Bharatam PV
    J Biomol Struct Dyn; 2015 Sep; 33(9):1913-28. PubMed ID: 25333695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors of multiple mutants of Plasmodium falciparum dihydrofolate reductase and their antimalarial activities.
    Kamchonwongpaisan S; Quarrell R; Charoensetakul N; Ponsinet R; Vilaivan T; Vanichtanankul J; Tarnchompoo B; Sirawaraporn W; Lowe G; Yuthavong Y
    J Med Chem; 2004 Jan; 47(3):673-80. PubMed ID: 14736247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis of solution-phase combinatorial library of 4,6-diamino-1,2-dihydro-1,3,5-triazine and identification of new leads against A16V+S108T mutant dihydrofolate reductase of Plasmodium falciparum.
    Vilaivan T; Saesaengseerung N; Jarprung D; Kamchonwongpaisan S; Sirawaraporn W; Yuthavong Y
    Bioorg Med Chem; 2003 Jan; 11(2):217-24. PubMed ID: 12470716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.